220 related articles for article (PubMed ID: 12182042)
1. [Environmental radiation exposure of a thyroid cancer patient resulting from adjuvant iodine radiotherapy].
Chaś J; Kowalczyk A; Siekierzyński M; Dziuk E; Janiak MK
Wiad Lek; 2001; 54 Suppl 1():312-20. PubMed ID: 12182042
[TBL] [Abstract][Full Text] [Related]
2. [Problems with radiation protection for adjuvant radiotherapy of thyroid cancer].
Siekierzyński M
Wiad Lek; 2001; 54 Suppl 1():307-11. PubMed ID: 12182040
[TBL] [Abstract][Full Text] [Related]
3. [Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: Therapeutic procedures].
Sudbrock F; Boldt F; Kobe C; Hammes J; Eschner W; Schicha H
Nuklearmedizin; 2009; 48(1):17-25. PubMed ID: 19212607
[TBL] [Abstract][Full Text] [Related]
4. Hospital discharge of patients with thyroid carcinoma treated with 131I.
Venencia CD; Germanier AG; Bustos SR; Giovannini AA; Wyse EP
J Nucl Med; 2002 Jan; 43(1):61-5. PubMed ID: 11801704
[TBL] [Abstract][Full Text] [Related]
5. Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
de Carvalho JW; Sapienza M; Ono C; Watanabe T; Guimarães MI; Gutterres R; Marechal MH; Buchpiguel C
Nucl Med Commun; 2009 Jul; 30(7):533-41. PubMed ID: 19436231
[TBL] [Abstract][Full Text] [Related]
6. [Exposure of relatives of patients after stationary radioiodine therapy by inhalation of 131I in their homes].
Wellner U; Eschner W; Hillger HW; Schicha H
Nuklearmedizin; 1998 May; 37(3):113-9. PubMed ID: 9604232
[TBL] [Abstract][Full Text] [Related]
7. Treatment of thyroid carcinoma: emphasis on high-dose 131I outpatient therapy.
Parthasarathy KL; Crawford ES
J Nucl Med Technol; 2002 Dec; 30(4):165-71; quiz 172-3. PubMed ID: 12446749
[TBL] [Abstract][Full Text] [Related]
8. Radiation dose to family members of hyperthyroidism and thyroid cancer patients treated with 131I.
Pant GS; Sharma SK; Bal CS; Kumar R; Rath GK
Radiat Prot Dosimetry; 2006; 118(1):22-7. PubMed ID: 16105892
[TBL] [Abstract][Full Text] [Related]
9. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
11. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay.
Watanabe N; Yokoyama K; Kinuya S; Shuke N; Shimizu M; Futatsuya R; Michigishi T; Tonami N; Seto H; Goodwin DA
J Nucl Med; 1998 Mar; 39(3):436-40. PubMed ID: 9529288
[TBL] [Abstract][Full Text] [Related]
12. Radiation exposure for 'caregivers' during high-dose outpatient radioiodine therapy.
Marriott CJ; Webber CE; Gulenchyn KY
Radiat Prot Dosimetry; 2007; 123(1):62-7. PubMed ID: 16825250
[TBL] [Abstract][Full Text] [Related]
13. 131I ablation treatment in young females after the Chernobyl accident.
Travis CC; Stabin MG
J Nucl Med; 2006 Oct; 47(10):1723-7. PubMed ID: 17015910
[TBL] [Abstract][Full Text] [Related]
14. Correlation between external exposure and activity in patients undergoing 131I thyroid cancer therapy.
Barquero R; Basurto F; Vega-Carrillo HR; Iñiguez MP; Ferrer N; Esteban R
Health Phys; 2008 Aug; 95(2):227-33. PubMed ID: 18617804
[TBL] [Abstract][Full Text] [Related]
15. [Measurement of incorporation in family members of radioiodine therapy patients after therapy of benign thyroid diseases].
Lassmann M; Hänscheid H; Schelper LF; Körber C; Reiners C
Nuklearmedizin; 1998 May; 37(3):120-3. PubMed ID: 9604233
[TBL] [Abstract][Full Text] [Related]
16. Labelled amino acids in plasma of patients with thyrotoxicosis and thyroid cancer after radioiodine treatment.
Bednár J; Nĕmec J; Soutorová M; Neradilová M; Pohunková D; Zamrazil V; Vána S; Havelka J; Röhling S
Endocrinol Exp; 1979 Mar; 13(1):53-63. PubMed ID: 316382
[TBL] [Abstract][Full Text] [Related]
17. Incidence of radiation thyroiditis and thyroid remnant ablation success rates following 1110 MBq (30 mCi) and 3700 MBq (100 mCi) post-surgical 131I ablation therapy for differentiated thyroid carcinoma.
Cherk MH; Kalff V; Yap KS; Bailey M; Topliss D; Kelly MJ
Clin Endocrinol (Oxf); 2008 Dec; 69(6):957-62. PubMed ID: 18419785
[TBL] [Abstract][Full Text] [Related]
18. Radioactivity of blood samples taken from thyroidectomized thyroid carcinoma patients after therapy with (131)I.
Larkin A; Millan E; Noz M; Wagner S; Friedman K; Blum M
Thyroid; 2011 Sep; 21(9):1009-12. PubMed ID: 21834682
[TBL] [Abstract][Full Text] [Related]
19. [Consensus proposal on the use of 131I in the treatment of thyrotoxicosis and thyroid cancer].
Michaud P
Rev Med Chil; 1998 Jul; 126(7):855-65. PubMed ID: 9830780
[TBL] [Abstract][Full Text] [Related]
20. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
